Table 6 Efficacy evaluation on D28 after PCR correction by center (ITT population)
Clinical evaluation | ASAQ1 (N = 310) | ASAQ2 (N = 315) | AL (N = 311) | Total (N = 936) |
|---|---|---|---|---|
Cameroon | ||||
Possible failure (information unavailable) | 3 (5.6%) | 8 (14.5%) | 4 (7.1%) | 15 (9.1%) |
Early treatment failure | 0 | 0 | 0 | 0 |
Late clinical failure | 0 | 0 | 0 | 0 |
Late parasitological failure | 0 | 0 | 0 | 0 |
Adequate clinical and parasitological response | 51 (94.4%) | 47 (85.5%) | 52 (92.9%) | 150 (90.9%) |
Madagascar | ||||
Possible failure (information unavailable) | 0 | 2 (3.3%) | 0 | 2 (1.1%) |
Early treatment failure | 0 | 0 | 0 | 0 |
Late clinical failure | 0 | 0 | 1 (1.7%) | 1 (0.6%) |
Late parasitological failure | 1 (1.7%) | 0 | 0 | 1 (0.6%) |
Adequate clinical and parasitological response | 58 (98.3%) | 58 (96.7%) | 59 (98.3%) | 175 (97.8%) |
Mali | ||||
Possible failure (information unavailable) | 2 (3.0%) | 3 (4.4%) | 2 (3.0%) | 7 (3.5%) |
Early treatment failure | 0 | 0 | 0 | 0 |
Late clinical failure | 0 | 0 | 0 | 0 |
Late parasitological failure | 2 (3.0%) | 0 | 2 (3.0%) | 4 (2.0%) |
Adequate clinical and parasitological response | 62 (93.9%) | 65 (95.6%) | 63 (94.0%) | 190 (94.5%) |
Senegal – Keur Soce | ||||
Possible failure (information unavailable) | 2 (2.1%) | 1 (1.1%) | 2 (2.2%) | 5 (1.8%) |
Early treatment failure | 0 | 0 | 0 | 0 |
Late clinical failure | 0 | 0 | 0 | 0 |
Late parasitological failure | 0 | 0 | 1 (1.1%) | 1 (0.4%) |
Adequate clinical and parasitological response | 93 (97.9%) | 91 (98.9%) | 86 (96.6%) | 270 (97.8%) |
Senegal – Mlomp | ||||
Possible failure (information unavailable) | 5 (13.9%) | 2 (5.0%) | 1 (2.6%) | 8 (7.0%) |
Early treatment failure | 0 | 0 | 0 | 0 |
Late clinical failure | 0 | 0 | 1 (2.6%) | 1 (0.9%) |
Late parasitological failure | 0 | 0 | 0 | 0 |
Adequate clinical and parasitological response | 31 (86.1%) | 38 (95.0%) | 37 (94.9%) | 106 (92.2%) |